Cancer of Exocrine Pancreas

No abstract is available for this paper.

• Publication year

  2021

• Venue

  Practical Medical Oncology Textbook

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1007/978-3-030-56051-5_40
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

  2023cited by this paper
• The Tumor-Agnostic Treatment For Patients with Solid Tumors: a Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBIOC-SIF Italian Scientific Societies.

  2021cited by this paper
• Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge

  2021cited by this paper
• Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

  2019cited by this paper
• Data Sources

  2018cited by this paper
• Targeting Epigenetic Aberrations in Pancreatic Cancer, a New Path to Improve Patient Outcomes?

  2018cited by this paper
• Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins

  2018cited by this paper
• Overexpression of HER2 in the pancreas promotes development of intraductal papillary mucinous neoplasms in mice

  2018cited by this paper
• Investigational agents to enhance the efficacy of chemotherapy or radiation in pancreatic cancer.

  2018cited by this paper
• Cancer statistics, 2018

  2018cited by this paper
• Therapeutic developments in pancreatic cancer: current and future perspectives

  2018cited by this paper
• Second-line chemotherapy for the treatment of metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy: a network meta-analysis

  2018cited by this paper
• Mucinous cystic neoplasms of the liver and pancreas: relationship between KRAS driver mutations and disease progression

  2017cited by this paper
• Intraductal Papillary Mucinous Neoplasms of the Pancreas: Strategic Considerations

  2017cited by this paper
• Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

  2017cited by this paper
• Evaluation of K-ras and p53 expression in pancreatic adenocarcinoma using the cancer genome atlas

  2017cited by this paper
• The TGF-β/Smad4 Signaling Pathway in Pancreatic Carcinogenesis and Its Clinical Significance

  2017cited by this paper
• Genomic Characterization of Low- and High-Grade Pancreatic Mucinous Cystic Neoplasms Reveals Recurrent KRAS Alterations in “High-Risk” Lesions

  2017cited by this paper
• Genome-wide DNA methylation analysis reveals molecular subtypes of pancreatic cancer

  2017cited by this paper
• A p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer.

  2017cited by this paper
• Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.

  2017cited by this paper
• KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer

  2017cited by this paper
• Improving post-surgical management of resected pancreatic cancer.

  2017cited by this paper
• Dynamic landscape of pancreatic carcinogenesis reveals early molecular networks of malignancy

  2016cited by this paper
• Epidemiology of pancreatic cancer

  2016cited by this paper
• Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.

  2016cited by this paper
• Pancreatic cancer: yesterday, today and tomorrow.

  2016cited by this paper
• APACT: Phase III randomized trial of adjuvant treatment with nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with resected pancreatic cancer (PC).

  2016cited by this paper
• Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.

  2016cited by this paper
• European cancer mortality predictions for the year 2016 with focus on leukaemias.

  2016cited by this paper
• Mortality in vegetarians and comparable nonvegetarians in the United Kingdom123

  2015cited by this paper
• Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2015cited by this paper
• Laparoscopic Versus Open Distal Pancreatectomy for Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis

  2015cited by this paper
• Demographics, epidemiology, and inheritance of pancreatic ductal adenocarcinoma.

  2015cited by this paper
• Consumption of fruit and vegetables reduces risk of pancreatic cancer: evidence from epidemiological studies

  2015cited by this paper
• Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

  2015cited by this paper
• Risk factors for pancreatic cancer: a summary review of meta-analytical studies.

  2015cited by this paper
• Population Attributable Risk for Pancreatic Cancer in Northern Italy

  2015cited by this paper
• Endoscopic and operative palliation strategies for pancreatic ductal adenocarcinoma.

  2015cited by this paper
• Preoperative endoscopic ultrasound-guided fine needle aspiration does not impair survival of patients with resected pancreatic cancer

  2015cited by this paper
• Gradual Telomere Shortening and Increasing Chromosomal Instability among PanIN Grades and Normal Ductal Epithelia with and without Cancer in the Pancreas

  2015cited by this paper
• Health-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally Advanced Pancreatic Cancer

  2015cited by this paper
• Molecular Biomarkers for Progression of Intraductal Papillary Mucinous Neoplasm of the Pancreas

  2015cited by this paper
• Pathogenesis of Pancreatic Cancer

  2014cited by this paper
• Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS).

  2014cited by this paper
• Genetic predisposition to pancreatic cancer.

  2014cited by this paper
• Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium.

  2014cited by this paper
• European cancer mortality predictions for the year 2014.

  2014cited by this paper
• Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens.

  2014cited by this paper
• Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer.

  2014cited by this paper
• Association of Diabetes Mellitus and Pancreatic Adenocarcinoma: A Meta-Analysis of 88 Studies

  2014cited by this paper
• Germline copy number variation in the YTHDC2 gene: does it have a role in finding a novel potential molecular target involved in pancreatic adenocarcinoma susceptibility?

  2014cited by this paper
• SMAD4 and its role in pancreatic cancer

  2014cited by this paper
• Question Sets and Answers

  2014cited by this paper
• MUC1 and HER2 might be associated with invasive phenotype of intraductal papillary mucinous neoplasm.

  2013cited by this paper
• Selected cancers with increasing mortality rates by educational attainment in 26 states in the United States, 1993–2007

  2013cited by this paper
• Carcinogenesis of Pancreatic Adenocarcinoma: Precursor Lesions

  2013cited by this paper
• Clinicopathological Correlates of Activating GNAS Mutations in Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas

  2013cited by this paper
• Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor–vessel relationships

  2013cited by this paper
• Clinical and molecular characterization of HER2 amplified-pancreatic cancer

  2013cited by this paper
• Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.

  2013cited by this paper
• Precancerous lesions of the pancreas.

  2013cited by this paper
• Pancreaticoduodenectomy following chemoradiotherapy for locally advanced adenocarcinoma of the pancreatic head.

  2013cited by this paper
• Prevalence of Diabetes Mellitus in Pancreatic Cancer Compared to Common Cancers

  2013cited by this paper
• Analysis of Germline Gene Copy Number Variants of Patients with Sporadic Pancreatic Adenocarcinoma Reveals Specific Variations

  2013cited by this paper
• Pancreatic cancer: why is it so hard to treat?

  2013cited by this paper
• Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials.

  2013cited by this paper
• Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear dose-response meta-analysis of prospective studies.

  2012cited by this paper
• Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia.

  2012cited by this paper
• Long-term results of resection of adenocarcinoma of the body and tail of the pancreas using radical antegrade modular pancreatosplenectomy procedure.

  2012cited by this paper
• Intraductal Papillary Mucinous Neoplasm of the Pancreas: An Update

  2012cited by this paper
• Red and processed meat consumption and risk of pancreatic cancer: meta-analysis of prospective studies

  2012cited by this paper
• Genetic susceptibility to pancreatic cancer

  2012cited by this paper
• Survival from common and rare cancers in Germany in the early 21st century.

  2012cited by this paper
• Pancreatic cancer: Overview of descriptive epidemiology

  2012cited by this paper
• Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues

  2012cited by this paper
• Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators

  2012cited by this paper
• Influence of Diet and Tobacco Smoking on Pancreatic Cancer Incidence in Poland in 1960–2008

  2012cited by this paper
• Pancreatic cancer risk: Associations with meat‐derived carcinogen intake in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) cohort

  2012cited by this paper
• Carcinogenesis of pancreatic cancer: Challenges, collaborations, progress

  2012cited by this paper
• Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.

  2011cited by this paper
• Is It Worth Looking? Abdominal Imaging After Pancreatic Cancer Resection: a National Study

  2011cited by this paper
• Recurrent GNAS Mutations Define an Unexpected Pathway for Pancreatic Cyst Development

  2011cited by this paper
• FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

  2011cited by this paper
• Diabetes and risk of pancreatic cancer: a pooled analysis of three large case–control studies

  2011cited by this paper
• Pancreatic cancer; reporting and long-term survival in Sweden

  2011cited by this paper
• Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data

  2011cited by this paper
• 16. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010

  2011cited by this paper
• Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas

  2011cited by this paper
• High-Throughput Mutation Profiling in Intraductal Papillary Mucinous Neoplasm (IPMN)

  2011cited by this paper
• Pancreatic cancer

  2011cited by this paper
• Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways

  2011cited by this paper
• Pancreatic exocrine insufficiency: Diagnosis and treatment

  2011cited by this paper
• A pooled analysis of 14 cohort studies of anthropometric factors and pancreatic cancer risk

  2011cited by this paper
• The role of radiotherapy in management of pancreatic cancer.

  2011cited by this paper
• Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5‐fluorouracil, and cisplatin followed by radiotherapy and 5‐fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma

  2010cited by this paper
• Preoperative biliary drainage for cancer of the head of the pancreas.

  2010cited by this paper
• Management of cancer pain: ESMO Clinical Practice Guidelines.

  2010cited by this paper
• Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages

  2010cited by this paper
• Differential cell cycle and proliferation marker expression in ductal pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia (PanIN)

  2010cited by this paper

• No citing papers are available for this paper.